Operating Units & Divisions
Board of Directors
Cell Systems Informatics
Neurospora & Agaricus Platforms
Endometrial Regenerative Cells
Porcine Research Models
Exclusive Channel Collaborations
Intrexon Institute for Biomolecular Research
At Intrexon we are committed to building…
A Better World Through Better DNA™
Whether engineering novel therapies in health, delivering unique solutions to address global energy demand, enabling unparalleled productivity advancements in food, or developing innovative applications in the consumer and environment sectors, we are working diligently today to create a better tomorrow.
Engineering novel solutions in
to achieve improved outcomes
Building a sustainable path to produce healthy, affordable
Utilizing a proprietary bioconversion platform for efficient
Developing innovative solutions for the
Designing bio based
Precise Gene Expression: Proprietary RheoSwitch
Engineering Microbes for Commercial Products:
From Fuels and Chemicals to APIs
Industry Leading Reproductive Technologies
IN THE NEWS
Intrexon to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
4/30/2015 5:00:29 AM
GERMANTOWN, Md., April 30, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Randal J. Kirk, Chairman and Chief Executive Officer, and Krish Krishnan, Chief Operating Officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12th, at 8:40 a.m. Pacific Standard Time at Encore at the Wynn, Las Vegas, Nevada. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer sectors to create biologically-based products that improve the quality of life and the health of the ...
Intrexon Completes Acquisition of Okanagan Specialty Fruits
4/20/2015 5:00:28 AM
Healthy Produce Choices for Consumers With Benefits Across Entire Supply Chain GERMANTOWN, Md., April 20, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has completed the acquisition of Okanagan Specialty Fruits (OSF), the pioneering agricultural company behind the Arctic® apple, the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives. OSF's vision and ground-breaking effort in responsibly harnessing the power of technology to produce wholesome, nutritious food that is more appetizing and convenient to consumers is aligned with Intrexon's strategy in the Food sector. The combi...
Driving Sustainable Agriculture through Improved Qualities in Eucalyptus and Poplar Trees
4/15/2015 5:01:10 AM
Intrexon and FuturaGene Collaborate to Develop Unique Attributes and Agronomic Properties in Significant Plant Species GERMANTOWN, Md. and SAO PAULO, April 15, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and FuturaGene Group, a wholly owned subsidiary of Suzano Papel e Celulose S.A., the second largest producer of eucalyptus pulp in the world, today announced they have entered into an exclusive collaboration to increase biomass in eucalyptus and poplar trees. FuturaGene has established itself as a leader in the development of sustainable solutions for global forestry, biofuel and agricultural markets through its proficiency in taking optimal tra...
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
3/30/2015 5:14:00 AM
BOSTON and GERMANTOWN, Md., March 30, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreeme...